Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

The treatment of HR+/HER2- metastatic breast cancer with cyclin-dependent kinases 4 and 6 inhibitors combined with endocrine therapy has recently emerged as the most relevant therapeutic strategy. However, in routine clinical practice, the best therapeutic approach in patients with comorbidities at...

Full description

Bibliographic Details
Main Authors: Alessandra Fabi, Giuseppe Buono, Emilio Bria, Giampaolo Bianchini, Giuseppe Curigliano, Michelino De Laurentiis, Sabino De Placido, Lucia Del Mastro, Valentina Guarneri, Daniele Generali, Lorenzo Livi, Vito Lorusso, Filippo Montemurro, Fabio Puglisi, Paolo Vigneri, Alberto Zambelli, Grazia Arpino
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
metastatic HR+/HER2-breast cancer
Delphi survey
CDK4/6i
oncology
consensus
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.950861/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.950861/full

Similar Items